News briefing: Chi-Med entrusts Inmagene with four preclinical programs; Xofluza nets EU approval for flu prevention
Longtime OrbiMed partner Jonathan Wang is starting the year off at his latest venture, Inmagene, with a slate of new preclinical drug candidates.
The …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
